Category - News

Developments

iBio in pact with EdgePoint AI for next generation quality in biologics manufacturing

iBio (NYSE AMERICAN:IBIO) entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence/blockchain-driven vision system for...

December 23, 2019

Markets

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

December 23, 2019

Markets

BTIG cuts Valeritas Holdings to neutral; removes PT

BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...

December 23, 2019

Markets

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

December 23, 2019

Developments

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...

December 20, 2019

Developments

Aravive begins enrollment for Phase 2a kidney fibrosis trial

Aravive (NASDAQ:ARAV) has begun enrolling patients in its Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN). IgAN occurs when an antibody called...

December 20, 2019

Developments

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...

December 20, 2019

Developments

Concert Pharmaceuticals completes alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...

December 20, 2019

Markets

HCW starts Ocugen at buy; PT $1.25

H.C. Wainwright launched coverage of Ocugen (NASDAQ:OCGN) with a “buy” rating and price target of $1.25. The stock closed at 36 cents on Dec. 19. Ocugen is developing therapies for rare and underserved eye diseases and...

December 20, 2019

Developments

Selecta completes enrollment in Phase 2 chronic refractory gout trial

Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout. SEL-212 is designed to sustain control of serum uric acid (SUA) levels in...

December 19, 2019

Category - News

iBio in pact with EdgePoint AI for next generation quality in biologics manufacturing

Roth starts Crinetics Pharma at buy; PT $37

BTIG cuts Valeritas Holdings to neutral; removes PT

Roth starts Oxurion at buy; PT €9

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Aravive begins enrollment for Phase 2a kidney fibrosis trial

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Concert Pharmaceuticals completes alopecia areata trial

HCW starts Ocugen at buy; PT $1.25

Selecta completes enrollment in Phase 2 chronic refractory gout trial

General

More